PBYI Relative Valuation
PBYI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PBYI is overvalued; if below, it's undervalued.
Historical Valuation
Puma Biotechnology Inc (PBYI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -74.35. The fair price of Puma Biotechnology Inc (PBYI) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：5.26
Fair
11.16
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Puma Biotechnology Inc. (PBYI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 5.89. The thresholds are as follows: Strongly Undervalued below -12.89, Undervalued between -12.89 and -3.50, Fairly Valued between 15.27 and -3.50, Overvalued between 15.27 and 24.66, and Strongly Overvalued above 24.66. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
6.80
EV/EBIT
Puma Biotechnology Inc. (PBYI) has a current EV/EBIT of 6.80. The 5-year average EV/EBIT is -193.03. The thresholds are as follows: Strongly Undervalued below -2042.98, Undervalued between -2042.98 and -1118.00, Fairly Valued between 731.95 and -1118.00, Overvalued between 731.95 and 1656.92, and Strongly Overvalued above 1656.92. The current Forward EV/EBIT of 6.80 falls within the Historic Trend Line -Fairly Valued range.
1.14
PS
Puma Biotechnology Inc. (PBYI) has a current PS of 1.14. The 5-year average PS is 0.88. The thresholds are as follows: Strongly Undervalued below 0.12, Undervalued between 0.12 and 0.50, Fairly Valued between 1.26 and 0.50, Overvalued between 1.26 and 1.64, and Strongly Overvalued above 1.64. The current Forward PS of 1.14 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Puma Biotechnology Inc. (PBYI) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.83. The thresholds are as follows: Strongly Undervalued below -33.45, Undervalued between -33.45 and -16.31, Fairly Valued between 17.97 and -16.31, Overvalued between 17.97 and 35.11, and Strongly Overvalued above 35.11. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
3.98
P/FCF
Puma Biotechnology Inc. (PBYI) has a current P/FCF of 3.98. The 5-year average P/FCF is -2.39. The thresholds are as follows: Strongly Undervalued below -90.88, Undervalued between -90.88 and -46.63, Fairly Valued between 41.86 and -46.63, Overvalued between 41.86 and 86.10, and Strongly Overvalued above 86.10. The current Forward P/FCF of 3.98 falls within the Historic Trend Line -Fairly Valued range.
Puma Biotechnology Inc (PBYI) has a current Price-to-Book (P/B) ratio of 2.27. Compared to its 3-year average P/B ratio of 3.94 , the current P/B ratio is approximately -42.39% higher. Relative to its 5-year average P/B ratio of -14.38, the current P/B ratio is about -115.78% higher. Puma Biotechnology Inc (PBYI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 13.80%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.15% , the current FCF yield is about -100.00% lower.
2.31
P/B
Median3y
3.94
Median5y
-14.38
16.39
FCF Yield
Median3y
13.80
Median5y
7.15
Competitors Valuation Multiple
The average P/S ratio for PBYI's competitors is 0.00, providing a benchmark for relative valuation. Puma Biotechnology Inc Corp (PBYI) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -32.36%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PBYI increased by 73.44% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 2.94 to 7.11.
The secondary factor is the Revenue Growth, contributed -32.36%to the performance.
Overall, the performance of PBYI in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Puma Biotechnology Inc (PBYI) currently overvalued or undervalued?
What is Puma Biotechnology Inc (PBYI) fair value?
How does PBYI's valuation metrics compare to the industry average?
What is the current P/B ratio for Puma Biotechnology Inc (PBYI) as of Dec 05 2025?
What is the current FCF Yield for Puma Biotechnology Inc (PBYI) as of Dec 05 2025?
What is the current Forward P/E ratio for Puma Biotechnology Inc (PBYI) as of Dec 05 2025?